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In Brief Cestari et al. identified steps of the inositol phosphate pathway that are essential for Trypanosoma brucei infection. Using a chemical genetic approach they discovered small molecules that inhibit phosphorylation of Ins(1,4,5)P3 and Ins(1,3,4,5)P4 and that are lethal to T. brucei and other related parasites.
INTRODUCTION
Kinetoplastid parasites cause Chagas disease, human African trypanosomiasis (HAT), and leishmaniases, which together affect more than 2 million people annually worldwide (Stuart et al., 2008) . Chagas disease is caused by Trypanosoma cruzi and affects people in South and Central America, although it has also spread to the United States (Bern, 2015) . Trypanosoma brucei primarily affects sub-Saharan Africa and causes HAT (or Nagana in cattle), and Leishmania spp. occur in more than 90 countries in the tropics, subtropics, and parts of Europe (Stuart et al., 2008) . Current drugs available for treating these diseases are inefficient and highly toxic, and drug resistance is spreading (Renslo and McKerrow, 2006; Stuart et al., 2008) . Thus there is an urgent unmet need for safe and effective drugs against these pathogens.
Typical drug discovery efforts against kinetoplastids have included untargeted inhibitor screens and repurposing approaches (Pena et al., 2015; Planer et al., 2014) . Although these approaches have met with some success, the lack of ligandtarget knowledge hinders chemical improvement of hits, and questions of target specificity are also difficult to resolve. The development of target-based inhibitors is an attractive approach for addressing some of these concerns; however, few targets have been validated in T. cruzi or Leishmania due to their limited genetic tractability. Advances in T. brucei genetics have allowed genome-wide gene essentiality screens and the validation of new targets and chemotypes for the development of novel drugs (Alsford et al., 2011; Cestari and Stuart, 2013; Kalidas et al., 2014) . Since the genomes of these parasites are highly conserved ($94% synteny and $60% overall identity of orthologous genes) (El-Sayed et al., 2005) , the identification of new targets and discovery of T. brucei-specific inhibitors may be useful for chemical validation of orthologous enzymes in T. cruzi and Leishmania spp.
The inositol phosphate (IP) pathway ( Figure 1 ) plays important roles in regulating essential biological processes from yeast to humans, including mRNA transport from the nucleus to the cytoplasm (Wickramasinghe et al., 2013) , transcriptional regulation (Millard et al., 2013; Steger et al., 2003) , embryogenesis (Seeds et al., 2015) , endocytosis (Yamaoka et al., 2015) , and ciliary function and signal transduction (Chavez et al., 2015) . We recently showed that this pathway controls transcription and allelic exclusion of variant surface glycoprotein (VSG) genes in T. brucei (Cestari and Stuart, 2015) , allowing T. brucei to evade the host immune response. The IP pathway also regulates Ca likely due to the variety of processes that their metabolic products control (Millard et al., 2013; Watson et al., 2012) . Since their metabolic products often regulate protein function by direct interaction, IP pathway enzymes are attractive targets for antiparasitic drugs.
Here, we show that almost every step of the T. brucei IP pathway contains a gene that is essential for growth, and some are essential for infection. Using chemogenetics we identified inhibitors that target enzymes of this pathway, including two series that inhibit TbIPMK. This enzyme phosphorylates inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) and inositol-1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4) and diverges substantially from its human ortholog. Inositol polyphosphate multikinase (IPMK) inhibitors were effective against related kinetoplastid IPMKs and inhibited T. cruzi amastigote proliferation. Thus, IP enzymes are potential drug targets and IPMK inhibitors may provide the basis for the development of new antiparasitic drugs.
RESULTS

T. brucei IP Pathway Genes Are Essential for Infection of Mice
We first sought to identify candidate drug targets in the T. brucei IP pathway. We knocked out various genes in the pathway and tested the ability of the resultant parasites to infect mice. We initially attempted to generate null cell lines by replacing both endogenous alleles of each target gene with drug resistance markers. In cases where null cells could not be obtained, we generated conditional null (CN) cells by replacing both endogenous alleles in cells that transcribe an ectopic copy of the target gene under tetracycline (tet) control. Using this approach we showed previously that the genes encoding TbPIP5K1, TbPIP5Pase1, TbIPMK, and TbCDS enzymes were essential for T. brucei BF growth in vitro, whereas TbIMPase1 was not essential (Cestari and Stuart, 2015) (Table 1 ). We show here that genes encoding a predicted TbPIP5Pase2 and TbIP5Pase are not essential for growth of T. brucei BF, although knockdown of TbPIP5Pase2 slightly reduced parasite growth (Table 1 and Figure S1 ). We obtained null BF cells for genes en- Arrows indicate enzyme reactions, with enzymes manipulated in the present study indicated in green and italicized. Open circles, essential genes; closed circles, non-essential genes; blue, overexpressed genes; red, knockdown or nulls in chemogenetic experiments. A gray square indicates an enzyme whose activity has not been studied or a gene essentiality that has not been analyzed. The red circles with white asterisks indicate TbSYJ1, which is annotated as synaptojanin (N-terminal domain) and is predicted to be a PI/IP 5-phosphatase. At least two genes encode enzymes with TbPIP5K, TbPIP5Pase, and TbIMPase predicted activity. Annotation is based on predicted or demonstrated function (Table 1). coding TbPIP5K2, TbSYJ1 (synaptojanin, predicted IP/PI 5-phosphatase), and TbIMPase2, and found that these cells grew slightly slower ($7 hr doubling time) than the parental cell line (SM427, $6 hr doubling time) ( Figure S1 ). The genes encoding TbINOS, TbPIS, TbPI4K, and TbPI3K are also essential for BF growth (Hall et al., 2006; Smith, 2005, 2006b; Rodgers et al., 2007) . Altogether, these results indicate that at least eight of the 14 studied genes encoding enzymes of the IP pathway are essential for growth of BF T. brucei.
We infected mice with T. brucei BF CNs to test the in vivo essentiality of the genes encoding TbPIP5K1, TbPIP5Pase1, TbIPMK, and TbCDS, all of which were essential in vitro. Doxycycline (dox, a stable tet analog) was added to the drinking water of one group of mice (dox mice) 18 hr prior to infection to induce transcription of the ectopic target gene, while another group of mice had dox omitted from the drinking water (no-dox mice) to knock down transcription of the target gene. All mice in both groups became infected, but parasitemia in the dox mice reached lethal levels (>1.0 3 10 8 parasites/ml of blood) between 4 and 5 days post infection (Figures 2A and 2B ), whereas in nodox mice parasitemia was cleared for all four cell lines, indicating that these genes are all essential for infection. We also infected mice with null cell lines for TbPIP5K2, TbSYJ1, and TbIMPase2 ( Figures 2C and 2D ), none of which was essential for growth in vitro. We compared their parasitemias with that of the SM427 parental cell line and with a null for dolichol phosphate a-1,2-mannosyltransferase (TbDPM) gene, which is involved in GPI glycosylation. Mice infected with null TbSYJ1 and TbDPM cells had parasitemias that were similar to those of the parental line; all mice died at day 4 post infection. Mice infected with the TbPIP5K2 cell line survived slightly longer, although all were infected. However, mice infected with null TbIMPase2 cells initially had a low parasitemia that became undetectable until day 9 post infection, after which parasitemia rose with 14 hr doubling time (2.5-fold slower than wild-type). All mice died by day 15 post infection. Thus, although the TbIMPase2 null cells did not exhibit severe growth defects in vitro, they exhibited reduced infectivity in vivo. The reasons underlying this recrudescent parasitemia after a subpatent period are unknown, but may be due to the IP pathway role in regulating VSG gene expression (Cestari and Stuart, 2015) or IP requirements for GPI synthesis (Martin and Smith, 2006a) . Overall, at least four of the eight IP pathway genes essential for T. brucei BF in vitro are also essential for infection of mice, whereas one non-essential gene (TbIMPase2) is important for infectivity. Thus, almost every step of the pathway has a gene essential for T. brucei; hence they are targets for drug development.
Identification of Effective and Selective Inhibitors of Trypanosome Growth
To identify inhibitors of the IP pathway enzymes, we initially screened a GlaxoSmithKline (GSK) library of 520 compounds predicted to act on protein kinases and PI kinases and that had not been previously tested against T. brucei BF. We identified 130 compounds with EC 50 s (effective concentrations that inhibit BF growth by 50%) ranging from 2 nM to 10 mM ( Figure 3A and Table S1 ). Moreover, 48 compounds had an EC 50 <1 mM, 41 had an EC 50 between 1 and 3 mM, and 41 had an EC 50 between 3 and 10 mM. The remaining compounds were not inhibitory at concentrations up to 15 mM. Compound clustering by structural similarity revealed additional information on chemotypes (Table S1) .
We determined the EC 50 s of a subset of compounds (EC 50 < $1.5 mM) against HepG2 human hepatocytes. Of the 45 compounds that were tested, 23 did not affect HepG2 viability and growth at concentrations up to 15 mM. Most compounds with EC 50 s below 15 mM against HepG2 cells were still one to two orders of magnitude more selective against T. brucei, with some compounds being up to 400-fold more selective ( Figure 3A) . We tested the most potent and selective compounds against T. cruzi and found that 20 of these also significantly inhibited intracellular amastigote proliferation (Figures 3B and 6E ; Table  S1 ). Moreover, 67 of the 130 compounds were shown to be effective against the erythrocytic stage of Plasmodium falciparum 3D7 (Figures 3B) and 25 of these were also effective against the multidrug-resistant P. falciparum strain Dd2 (Gamo et al., 2010) . Overall, we found compounds that are selective and effective against trypanosomes and potential chemotypes for the development of antiparasitic drugs.
Chemogenetic Identification of T. brucei IP Pathway Inhibitors We next used a chemogenetic approach to identify compounds that target the IP pathway. We generated 11 cell lines in which expression of genes for specific steps in the pathway was either eliminated, knocked down, or overexpressed by using null, CN, or tet-regulatable overexpressor cells, respectively. These cells were screened with the T. brucei-selective compounds (EC 50 < $1.5 mM) to identify changes in cell sensitivity. Overexpression of a target enzyme is expected to modulate the compound inhibitory effect, i.e., increase the EC 50 . Elimination of a non-essential enzyme is predicted to generate cells dependent on the activity of a homologous enzyme and increase sensitivity to the inhibitor, i.e., lower EC 50 , or have other effects on drug sensitivity depending on the overall consequences of the loss of the function of the deleted gene.
We performed a blind screen using 50 compounds against the transgenic cells and included pentamidine, a drug used to treat T. brucei infection, as a control for assay reproducibility (Figure 4A) . Using a false discovery rate (FDR) of 1%, we identified seven compounds whereby gene overexpression increased the EC 50 of the compound, compared with non-induced or parental cell lines, by about 2-to 5-fold ( Figure 4B and Table  S2 ). ANOVA indicated that four of these changes were statistically significant. Overexpression of TbPI4K increased the EC 50 to C37 (p < 0.001), of TbIPMK to C20 (p < 0.01) and C44 Cestari and Stuart, 2015. b This work (see Figure S1 ).
c Hall et al., 2006. (p < 0.01), and of TbPIP5Pase1 to C29 (p < 0.001) and C41 (p < 0.001). These results imply that the compounds primarily act on these enzymes. Gene elimination or knockdown increased cell sensitivity to some compounds, resulting in as much as a 4.5-fold decrease in the EC 50 compared with parental cells (Figures 4A and 4C) . Conditional knockdown of TbIP5Pase decreased the EC 50 to C18 (p < 0.05) and C22 (p < 0.05), and conditional knockdown of TbPIP5Pase2 decreased the EC 50 to C19 (p < 0.05), C22 (p < 0.05), C43 (p < 0.05), C44 (p < 0.001), and C53 (p < 0.05). The knockdowns of TbIP5Pase or TbPIP5Pase2 increased sensitivity to C22, suggesting that this compound acts against 5-phosphatases ( Figure 1 ). On the other hand, knockdown of TbPIP5Pase2 or overexpression of TbIPMK altered sensitivity to C44, with the knockdown resulting in cells being more sensitive and the overexpression in cells being less sensitive to C44 ( Figure 4A ). The differential effect of C44 on these cell lines may be due to alterations of the pathway metabolic flux. Other compound treatments resulted in apparent changes in cell sensitivity, but not all of those were significant, possibly due to compound specificity. Thus, the chemogenetic analysis identified compounds that target enzymes of the IP pathway or processes related to the pathway function.
Enzymatic Validation of T. brucei IPMK Inhibitors
The chemogenetic data suggest that compounds C20 and C44 inhibit T. brucei IPMK. IPMKs are enzymes that phosphorylate soluble IPs downstream of phospholipase C and exhibit 6-/3-/ 5-kinase activity (Endo-Streeter et al., 2012; Holmes and Jogl, 2006) , with the exception of human IPMK, which also phosphorylates PI substrates (Maag et al., 2011) . T. brucei-predicted IPMK was annotated as a hypothetical protein and has not been characterized. TbIPMK exhibits only 12% amino acid identity with human IPMK, 13% with yeast, 8% with Drosophila, 5% with P. falciparum, and 45% and 35% with the predicted T. cruzi and Leishmania major enzymes, respectively. Nevertheless, key amino acids of the catalytic site including the IP binding domain and the SSLL and IDF signatures are conserved among kinetoplastid IPMKs and in other organisms ( Figure 5A ). Its divergence from human enzymes and its essentiality for infection ( Figure 2 ) make TbIPMK an attractive target candidate for drug development. We expressed and purified TbIPMK from Escherichia coli and tested the activity of the recombinant TbIPMK (rTbIPMK) with IP and PI metabolites (Figures 5B and 5C) . rTbIPMK phosphorylated soluble Ins(1,4,5)P3 and to a lesser extent Ins(1,3,4,5)P4 substrates, but not any of the other IP or PIs tested ( Figure 5C ). Enzymological analysis confirmed that rTbIPMK acts preferentially on Ins(1,4,5)P3 compared over Ins(1,3,4,5) P4, even at saturating substrate concentrations, with a rTbIPMK efficiency (K cat /K m ) about 6-fold higher for Ins(1,4,5)P3 than Ins(1,3,4,5)P4 ( Figure 5C , inset and Table S3 ). It is important to note that reactions in the presence of Ins(1,4,5)P3 could sequentially phosphorylate two inositol sites, yielding Ins(1,3,4,5)P4 and Ins(1,3,4,5,6)P5. Hence, T. brucei IPMK catalyzes the phosphorylation of specific soluble IPs and lacks activity against PIs, in contrast to its human ortholog.
We performed rTbIPMK inhibition assays with C44, C20, and related compounds using primarily I(1,4,5)P3 as a substrate . Compound C44 inhibited rTbIPMK activity with an IC 50 (a concentration that inhibits enzyme activity to 50% of the maximum) of 3.4 mM. Compound structure similarity analysis identified C38, C43, C122, and C216 as related to C44 (Figure S2) , and C38 and C216 each inhibited rTbIPMK with IC 50 s similar to that of C44. Although C38 and C216 have minor structural differences at the dichlorophenyl group ( Figure 5D ), the C38 EC 50 against T. brucei cells was 0.51 mM, similar to that of C44 (0.83 mM), whereas C216 was not inhibitory at concentrations up to 15 mM. In contrast, C43 and C122, both of which differ from C44 at the pyridopyrimidine group, had almost no activity against rTbIPMK ( Figure S2 ), suggesting that this chemical group may be important for the specificity of these inhibitors. Furthermore, C20 partially inhibited rTbIPMK activity, even at high concentrations ( Figure 5E ), but compound C52, which has a fluorine at a phenyl group ( Figures 5D and S2 ), completely inhibited rTbIPMK activity. Given the similarity of C20 and C52, it is likely that C20 activity against T. brucei IPMK in cell assays results from analogous products originating from C20 modifications in the cells. In addition, C44, and to a lesser extent C52, inhibited rTbIPMK activity in the presence of Ins(1,3,4,5)P4, the other TbIPMK substrate ( Figure 5G ).
Kinetic analysis showed that C44 inhibited rTbIPMK by decreasing its V max independently of substrate concentration with a K i of 5.0 mM ( Figure 5H ), indicating that C44 acts as a non-competitive inhibitor of rTbIPMK. However, C52 inhibited rTbIPMK with a K i of 3.2 mM and resulted in an apparent increase of the K m but no significant alterations of V max , indicating that C52 acts as a competitive inhibitor of rTbIPMK with respect to Ins(1,4,5)P3. Due to differences in these compound mechanisms of inhibition, it is likely that they inhibit rTbIPMK by interacting with different enzyme sites with C52 competing with the Ins(1,4,5)P3 binding site. Overall, T. brucei IPMK functions in the synthesis of inositol phosphate metabolites, and C44 and C20 represent two distinct classes of TbIPMK inhibitors. (Figure 6D ). However, cell sensitivity differed from compound to compound and also among the IPMK genes expressed. For example, T. brucei cells exclusively expressing TcIPMK were more sensitive to C20, C44, and C52 and less sensitive to C50 and C88 compared with cells expressing TbIPMK, whereas the exclusive expression of LmIPMK resulted in cells more sensitive to C33 and less sensitive to C38 than cells expressing TbIPMK. These differences may result from IPMK amino acid sequence variations between the parasites.
Finally, we analyzed the effects of IPMK inhibitors and additional selective compounds against T. cruzi intracellular amastigotes. Importantly, IPMK mRNA has been shown to be upregulated in T. cruzi amastigotes and trypomastigotes compared with noninfectious stages (Aslett et al., 2010) ; thus, if this gene is essential for T. cruzi amastigotes its inhibition would be lethal. We infected mammalian cells for 24 hr with T. cruzi Silvio X10/1 metacyclic trypomastigotes. At 72 hr post infection we added various compounds at 5 mM and quantified the numbers of intracellular amastigotes and infected cells at 120 hr post infection. Several compounds, including the C20 and C44 compound series, inhibited intracellular amastigote growth by >50% ( Figure 6E ). C44 only partially inhibited amastigote growth; however, its analogs C38 and C216 strongly inhibited amastigote proliferation by >70%. In addition, both C20 and C52 also inhibited amastigote proliferation by >50%. These data imply that TcIPMK inhibition is lethal to amastigotes and chemically validate T. cruzi IPMK as a target for drug development. Moreover, compounds C52 and C44 are chemotypes for the development of clinical inhibitors of kinetoplastid IPMKs.
DISCUSSION
The development of new drugs against kinetoplastid parasites has been hindered by the lack of knowledge of drug targets, target-specific chemotypes, and their modes of action. We show here that the IP pathway is a target for antikinetoplastid drug discovery. We found that eight genes of this pathway are essential for T. brucei BF growth, five of which are also important for infection. We identified 130 molecules that inhibited T. brucei growth, many of which were highly selective compared with mammalian cells. Using a chemogenetic approach that involved perturbation of IP pathway gene expression and compound screening, we identified compounds that target IP enzymes. Two series of compounds were biochemically validated as inhibitors of T. brucei IPMK. This enzyme phosphorylates Ins(1,4,5)P3 and Ins(1,3,4,5)P4 and diverges from human IPMK. Genetic complementation experiments showed that IPMKs are functionally conserved among kinetoplastids, and that IPMK inhibitors were effective against T. cruzi and L. major IPMKs and lethal for intracellular T. cruzi amastigotes. Thus, our chemogenetic approach using T. brucei as an experimental surrogate of less An attractive feature of the IP pathway as a drug target is that IP metabolites have multiple essential regulatory functions in eukaryotes. Hence, disruption of the pathway may have pleiotropic detrimental effects on the pathogen. This pathway has not been heavily studied in kinetoplastids, but is known to function in the control of VSG gene transcription and antigenic variation, acidocalcisome function, Golgi maintenance, and cytokinesis in T. brucei (Cestari and Stuart, 2015; Hall et al., 2006; Huang et al., 2013; Rodgers et al., 2007) , and likely in other processes. Our functional analyses using null and CN cell lines avoided the uncertainties related to insufficient gene knockdown in RNAibased approaches. All four genes that were essential in vitro were also essential for infection in mice, but one of the four non-essential genes in vitro was important for infection. For example, the null TbIMPase2 cells were partially cleared before establishing lethal infections. In addition, infections with CN TbPIP5K cells in the presence of dox showed variable parasitemia levels before establishing lethal infections (Figure 2) . Similar results were obtained with CN TbPIP5K in infections with various concentrations of dox, indicating that ample dox is present (not shown), and the in vitro growth rate of these cells in the presence of tet was the same as in wild-type cells (Cestari and Stuart, 2015) . We did not explore the basis for these cases of decreased parasitemia levels followed by the establishment of infection and mouse lethality. However, we previously showed that TbPIP5K regulates monoallelic expression of VSG genes and antigenic variation (Cestari and Stuart, 2015) , and TbIMPase2 is predicted to encode one of the two T. brucei enzymes that dephosphorylate Ins(1,4)P2. The product of this reaction may be utilized in the synthesis of GPIs, which anchor VSGs on the parasite surface (Martin and Smith, 2006a) . Because the in vivo growth profile of the CN TbPIP5K and null TbIMPase2 cells resembles a relapse due to antigenic switching, one possibility is that their antigenic switching is altered. Alternatively, perturbation of the IP pathway may have had other consequences on parasitehost interactions, given the numerous functions of these metabolites ( Table S2 ). Data are presented as mean.
In contrast to target-based screening against recombinant proteins (Pedro-Rosa et al., 2015) and compound repurposing strategies (Planer et al., 2014) , our chemogenetic approach took advantage of our knowledge of IP pathway enzyme essentiality and our ability to genetically manipulate T. brucei. Furthermore, potential target-based inhibitors were identified directly in T. brucei infectious stages. T. brucei sensitivity to ten compounds changed after genetic perturbation of the IP pathway. While the shift in EC 50 associated with the change in expression of a particular IP enzyme may reflect targeting of that enzyme by the compound, it may alternatively reflect alteration in IP metabolite flux or change in reliance on another, e.g., paralog, enzyme or process that is regulated by an IP metabolite. Since little is known about IP pathway metabolites and their flux and regulation, e.g., feedback loops and substrate-product conversion rates, we cannot pinpoint specific targets by this approach alone. However, chemogenetic data point the way for biochemical validation.
The chemogenetic results indicate that compounds C44 and C20 target T. brucei IPMK. Kinetoplastid parasites, which are diploids, have one IPMK gene. The likely two alleles in the T. cruzi Cl Brener strain, which is a hybrid, have >97% identity. T. brucei IPMK catalyzes the sequential phosphorylation of Ins(1,4,5)P3 into Ins(1,3,4,5)P4 and of this metabolite into inositol-1,3,4,5,6-pentakisphosphate. In contrast to human IPMKs (Maag et al., 2011) , this enzyme does not phosphorylate PI substrates. The sequence (<12% amino acid identity) and functional diversity from human IPMK and its essentiality for infection indicate that T. brucei, and perhaps the closely related kinetoplastid, IPMKs are useful targets for drug development. The precise function of IPMK in trypanosomes is unknown, but IPMK products regulate various processes in yeast and mammals, including nuclear mRNA export (Steger et al., 2003; Wickramasinghe et al., 2013) and the HDAC complex (Millard et al., 2013; Watson et al., 2012) .
Kinetic analysis showed that C44 inhibits rTbIPMK in the presence of both Ins(1,4,5)P3 or Ins(1,3,4,5)P4 substrates and acts as a non-competitive inhibitor, as may its analogs C38 and C216. C20 partially inhibited enzyme activity but its analog C52, from which it differs by a single fluorine, completely inhibited rTbIPMK activity. C52 acted as a competitive inhibitor of Ins(1,4,5)P3 but poorly inhibited rTbIPMK in the presence of Ins(1,3,4,5)P4. The differences in C52 inhibition with these substrates may be due to differences in IPMK requirements for substrate recognition, as suggested by structural and mutational analyses of orthologous IPMKs (Endo-Streeter et al., 2012; Holmes and Jogl, 2006) . Either type of inhibitor may be suitable for drug development, since both competitive and non-competitive inhibitors have become drugs against infectious agents (Sarafianos et al., 2009) .
Our chemogenetic and biochemical data suggest that T. brucei IP enzymes may be the primary targets of these Table S3 for details).
(D) Structure and activity information for compounds C44 and C20. Arrows with pink circles indicate modifications of analogous compounds (see Figure S2 for detailed structure and activity of analogs inhibitors, but they may also have secondary targets. The identification of analogs, such as the C52 and C20 or C44 series, also demonstrates the validity of the identified chemotypes. Some analogs were not identified as positive chemogenetic hits, which may be due to a combination of factors such as statistical stringency, compound transport, and/or intracellular compound modifications. Limitations of gene overexpression levels in trypanosomes may also have influenced the identification of less specific compounds. The IPMK inhibitors also inhibited T. cruzi and L. major IPMKs, which we show by genetic complementation experiments to be functionally conserved among kinetoplastids. In addition, IPMK inhibition was also lethal for intracellular T. cruzi amastigotes, demonstrating the potential value of this drug target in T. cruzi. This extends the short list of validated targets for drug development in T. cruzi, which includes cytochrome b, cruzain, sirtuins, and sterol 14a-demethylase (Doyle et al., 2010; Khare et al., 2015; McGrath et al., 1995; Moretti et al., 2015) . Some IPMK inhibitors are also effective against P. falciparum, suggesting that these inhibitors may be broadly used to develop new antiparasitic drugs. Overall, we identified kinetoplastid IP pathway enzymes that are druggable and two IPMK inhibitor chemotypes to aid the development of new drugs against kinetoplastids and, perhaps, other pathogens.
SIGNIFICANCE
Kinetoplastid parasites cause a spectrum of neglected tropical diseases that affect $2 million people annually worldwide. Current drug treatments are inadequate, and the development of new drugs has been hindered by a limited knowledge of drug targets and inhibitors, especially against T. cruzi and Leishmania spp., which are genetically less tractable. We used T. brucei as a surrogate system to identify new drug targets and employed a chemogenetic approach to identify target-based inhibitors. We focused on the IP pathway and genetically demonstrated that almost every step is essential for T. brucei. The pathway essentiality is likely due to various processes regulated by its metabolites, and highlights its biological importance and druggability. We identified inhibitors that target IP enzymes, specifically two chemotypes that inhibit IPMK with distinct mechanisms of action. We show that IPMK phosphorylates Ins(1,4,5)P3 and Ins(1,3,4,5)P4, well-known second messengers whose perturbation is anticipated to have pleiotropic effects. Moreover, IPMK inhibitors were selective to kinetoplastids compared with humans and also affected Plasmodium. Thus, these inhibitors promise to aid the development of drugs against kinetoplastids and perhaps other pathogens. These inhibitors will be useful to dissect the IP pathway function in T. cruzi and Leishmania spp., and demonstrate that our chemogenetic approach is a powerful method for advancing target-based drug discovery.
EXPERIMENTAL PROCEDURES Cell Culture
The T. brucei BF were maintained in HMI-9 medium supplemented with 10% fetal bovine serum (FBS) at 37 C in 5% CO 2 . SM427 and nulls were maintained with 2 mg/ml G418, and CNs with also 2.5 mg/ml of phleomycin and 0.5 mg/ml of tet. T. cruzi was maintained as epimastigotes in LIT medium at 28 C, and metacyclic trypomastigotes were obtained by DEAE-cellulose purification (Cestari and Ramirez, 2010) . L. major LT252 (MHOM/IR/1983/IR) were cultivated in M199 medium supplemented with 10% FBS, 100 mM adenine, 10 mg/ml heme, 40 mM HEPES (pH 7.4), 50 units/ml penicillin, and 50 mg of streptomycin. HepG2 and HeLa cells were maintained in DMEM supplemented with 10% FBS at 37 C in 5% CO 2 .
Transgenic Cell Lines and Growth Curves
Cell lines that conditionally express IP pathway genes, nulls, or CN cell lines were generated as described by Cestari and Stuart (2015) . GeneDB IDs are shown in Table 1 , except for TbPI4K and TbDPM which are Tb927.4.1140 and Tb927.6.1140, respectively. Cells that conditionally expressed a No cmp   C2  C3  C5  C6  C8  C10  C11  C12  C13  C14  C15  C16  C17  C19  C20  C23  C25  C29  C30  C33  C38  C41  C43  C44  C45  C47  C48  C52  C55  C66  C122 C-terminally V5-tagged protein were generated by introducing a tet-dependent allele containing three V5 tag sequences at its 3 0 terminus into the rRNA intergenic region of SM427 cells using pLEW100-3V5. T. brucei CN cells that exclusively expressed a T. cruzi (TcCLB.510741.110) or Leishmania major (LmjF.35.3140) IPMK gene were generated by transfection of pHD-1344-3V5, which contains a 3V5 tag at its 3 0 terminus for constitutive expression by integration into one of the tubulin loci. All genes were amplified from genomic DNA of T. brucei strain 427, T. cruzi strain Silvio X10/1, or L. major strain LT252 using specific primers (Table S4 ) and the DNeasy Blood & Tissue Kit (Qiagen) following the manufacturer's instructions. Gene replacements and insertions were confirmed by PCR and regulated RNA expression was determined by qRT-PCR analysis of cells grown in the presence or absence of 0.5-1.0 mg/ ml tet. Tet-induced (1.0 mg/ml) conditional protein expression was assayed by western analysis of cell lysates with anti-V5 (Life Technologies) and antimouse immunoglobulin G horseradish peroxidase-conjugated secondary antibodies (Pierce). Growth curves were obtained as previously described (Cestari and Stuart, 2015) , except that no drugs were used for null cells. Parasites were counted by Neubauer chambers or a particle counter (Beckman Coulter).
Mouse Experiments
T. brucei SM427, CN, or null cell lines growing at mid-log phase were used to infect BALB/cAnNHsd mice (6-to 8-week-old males; Harlan Laboratories).
Mice were injected intraperitoneally with 1.0 3 10 4 parasites in 200 ml of HMI-9 medium. Mice that were infected with CN cell lines were given drinking water 18 hr before infection containing 200 mg/ml doxycycline and 5% sucrose to induce expression of target genes, whereas gene knockdown was accomplished by giving the mice drinking water containing only 5% sucrose; water was replaced daily. Parasitemias were monitored daily by tail prick starting at 2 days post infection. Mice with a parasitemia of 1.0 3 10 8 parasites/ml of blood were euthanized. All procedures were performed in the vivarium of the Center for Infectious Disease Research in compliance with all applicable laws and institutional guidelines (Institutional Animal Care and Use Committee protocol KS-01).
Compound Assays A library of 520 compounds diluted at 10 mM in DMSO was provided by GSK. A screen was performed at 15 mM to identify compounds that inhibited T. brucei BF growth, and EC 50 s of 130 effective compounds were determined using 2-fold serial dilutions ranging from 15 mM to 0.029 mM (Cestari and Stuart, 2013) . For chemogenetic studies, survival assays were performed at the EC 50 of each compound, and fold changes between genetic modified and parental cell lines were calculated as (GMTOPTÞ3ðPNTOGMNTÞ, where GM is genetic modified cells (nulls/CNs or overexpression), P is parental cells (SM427 for nulls, non-induced for overexpression), T is compound treatment, and NT is not treated with compounds, which correct for differences in growth rate of cell lines. The relative EC 50 was calculated by multiplying the EC 50 of parental (SM427) by the survival fold change. For HepG2 EC 50 s, 1.5 3 10 4 cells/well were plated in 96-well plates and assays performed as described by Cestari and Stuart (2013) . For T. cruzi drug assays, HeLa cells were incubated in eight-well chamber slides (Fisher Scientific) at 5.0 3 10 3 cells/well for 24 hr at 37 C in 5% CO 2 , then incubated with metacyclic trypomastigotes (10:1) for 24 hr. Extracellular parasites were removed by pipetting and mammalian cells incubated for an additional 48 hr to ensure intracellular trypomastigote differentiation to amastigotes and initial replication. Next, compounds (5 mM) were added in 100 ml DMEM supplemented with 10% FBS, and the cells were incubated for 48 hr at 37 C in 5% CO 2 . The cells were washed, fixed in 100% cold methanol, and stained with Giemsa. The number of intracellular amastigotes per cell and the number of infected cells per total cells were quantified. The percentage of amastigote proliferation was calculated as ðamaOinfÞ3ðinfOtÞ, where ama is total intracellular amastigotes. inf infected cells. and t total cells. Infected cells not treated with compounds were set as 100%.
Enzyme Kinetics
The T. brucei gene encoding IPMK was cloned into pET-29a (Novagen) and expressed in E. coli DE3 pLysS Rosetta cells. Recombinant protein was purified using nickel-resin (Cestari and Stuart, 2015) . Protein activity was assayed using the ADP luciferase assay (Promega). IPs and diC8 PIs were purchased from Echelon Biosciences. Assays were performed in 25-ml reactions in 96-well plates using 20 mM HEPES, 150 mM NaCl, and 2 mM MgCl 2 (pH 7.5) at 37 C and 270 nM rTbIPMK. Substrate analysis was performed for 60 min with 50 mM of each substrate, and dose-response assays were performed with 1-200 mM Ins(1,4,5)P3 or Ins(1,2,4,5)P4 for 30 min. For inhibition assays all compounds were diluted in water and the reaction mixes incubated for 30 min. Ins(1,4,5)P3, Ins(1,3,4,5)P4, and ATP were used at 30, 40, and 50 mM, respectively. For K i analysis and mechanisms of enzyme inhibition, reactions were prepared with 10, 30, and 60 mM Ins(1,4,5)P3 and C44 (0, 1, 5, 10, and 25 mM) or C52 (2, 10, 20, and 40 mM). Kinetic analyses were calculated by non-linear regression using GraphPad Prism for Windows 5.03 (GraphPad Software). Compound analogs were identified using an atom pair method and Tanimoto coefficients using ChemmineR (Cao et al., 2008) .
Data Presentation and Statistical Analysis
Data are presented as mean ± SEM of at least three biological replicates. Comparisons among groups were made by two-tailed t test for repeated measures using GraphPad Prism. Values of p < 0.05 with a confidence interval of 95% were considered statistically significant. For chemogenetic interaction, FDR was calculated based on two-tailed normal distribution of combined data from SM427 and control cells (non-induced and non-knockdown). A 1% cutoff was used to define changes in fold change after overexpression or knockdown or from null cells. Two-way ANOVA with Bonferroni correction was used to determine whether fold changes were statistically significant with p < 0.05 and confidence interval of 95%. Graphs were prepared using GraphPad Prism or RStudio (R Core Team, 2015) . Table 1 Figure S2 . Structure activity relationship of C44 and C20 compound series against T. brucei rTbIPMK (related to Figure 5) . A-B) Structure of compounds (identified in our library) that are similar to C44 (A) or C20 (B). Pink shading indicates C44 or C20 compounds. C) Inhibition of rTbIPMK with C44 and C20 compound series. C44 compound series were tested at 3 µM concentrations whereas C20 series at 10 µM concentrations (see Fig 5) . Similarity scores of each C44 or C20 compound analogs were calculated using ChemmineR using the atom pair method. Data are represented as mean (± SEM).
SUPPLEMENTAL INFORMATION
C44
C216 C122 C43 C38
C20
C52
C65 C15 C33 C50 C54 Table S1 . Structure and activity information of all 520 compounds tested against T. brucei bloodstream forms (related to Figure 3 , please see excel file). EC50 of compounds tested against HepG2 cells, compounds effective against T. cruzi amastigotes tested at 5µM and EC50 of compounds tested against Plasmodium falciparum (Gamo, et al., 2010) are also indicated. Data are represented as mean. Figure 4) . Table shows genes and compounds that when tested in combination significantly altered T. brucei EC50 compared to parental cell lines. Data are represented as mean. Table S3 . Enzymatic parameters of T. brucei rTbIPMK (related to Figure 5 ). Data are represented as mean (± SEM). 
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